Published in Oncology Business Week, July 23rd, 2006
Having successfully divested non-oncology assets in 2005, the company is now focused on the development of its core oncology product programs which include ProLindac, an innovative polymer-platinum prodrug entering two phase II clinical trials, MuGard, a supportive care treatment of mucositis for patients undergoing radiation therapy and chemotherapy for cancer, and other early stage oncology compounds that utilize the company's unique drug delivery platforms. The company's restructuring efforts included a previously announced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week